MET and cancer: In addition, selective c‐met small‐molecule inhibitors have failed to gain approval due to adverse effects, dose‐limiting toxicities or acquired resistance; therefore, novel approaches that suppress HGF/c‐met signaling are needed.29 In the last decade, aptamers have emerged as attractive alternatives to antibodies and small molecules and have found use in diagnostic, therapeutic, imaging and targeting applications.30 A handful of aptamers have been developed to function as therapeutic agonists in cancer.